等待開盤 01-29 09:30:00 美东时间
-2.810
-1.66%
Virtus Investment Partners Inc. to Announce Fourth Quarter Results and Host Investor Call Virtus Investment Partners, Inc. will announce its fourth quarter 2025 financial results before the market opens on Friday, February 6, 2026. A conference call and webcast with the investment community, hosted
01-26 15:38
今日重点评级关注:Benchmark:维持TNL Mediagene"投机性买入"评级,目标价从3.5美元升至14美元;康托·菲茨杰拉德:维持Eupraxia Pharmaceuticals"超配"评级,目标价从11美元升至19美元
01-16 10:04
今日重点评级关注:HC Wainwright & Co.:维持Rezolve AI"买入"评级,目标价从10美元升至12美元;HC Wainwright & Co.:维持Largo"买入"评级,目标价从2.9美元升至3.1美元
01-15 16:10
Virtus Investment Partners (VRTS) on Tuesday reported preliminary assets under management of $159.5B as of December 31, 2025, compared to $164.2B as of November 30, 2025. Other fee-earning assets stoo...
01-13 20:58
Virtus Investment Partners, Inc. (NYSE:VRTS) today reported preliminary assets under management (AUM) of $159.5 billion and other fee earning assets of $1.8 billion for total client assets of $161.3 billion as of
01-13 20:09
今日重点评级关注:Truist Securities:维持拜玛林制药"买入"评级,目标价从80美元升至100美元;HC Wainwright & Co.:维持Savara"买入"评级,目标价从8美元升至10美元
2025-12-24 11:17
Piper Sandler analyst Crispin Love maintains Virtus Inv (NYSE:VRTS) with a Overweight and lowers the price target from $225 to $218.
2025-12-23 18:28
今日重点评级关注:巴克莱:维持Iovance Biotherapeutics"超配"评级,目标价从9美元升至10美元;摩根大通:上调Recursion Pharmaceuticals评级至"超配",目标价从10美元升至11美元
2025-12-18 10:54
An update from Virtus Investment Partners ( ($VRTS) ) is now available. On Dece...
2025-12-16 22:17
今日重点评级关注:杰富瑞:维持ImmunityBio Inc Ordinary Shares"买入"评级,目标价从8美元升至9美元;B. Riley证券:维持WAVE Life Sciences"买入"评级,目标价从19美元升至37美元
2025-12-15 15:30